Schedule Now

Retatrutide is an investigational medication currently being studied for its potential role in weight management and metabolic health. As interest in next-generation incretin-based therapies continues to grow, many individuals are searching for clear, accurate updates on where retatrutide stands in the regulatory process.

This page outlines retatrutide’s approval status, covering clinical trial progress, regulatory milestones, and remaining steps before potential availability. Information is based on current research and presented without added interpretation.

If you’re new to this topic, you may also find it helpful to review our overview of what retatrutide is and how retatrutide works, which explain its mechanism and current research focus in more detail.
As of now, retatrutide is not approved by the U.S. Food and Drug Administration (FDA) or other major regulatory agencies for any indication.

It is still undergoing clinical trials to evaluate:

  • Safety
  • Effectiveness
  • Appropriate dosing
  • Long-term outcomes

Approval decisions depend on the results of these trials and subsequent regulatory review.

Retatrutide has progressed into late-stage clinical trials (Phase 3) for certain indications, including weight management and metabolic conditions.

Clinical trial phases generally include: